STRATEGY

Uni-Bio Science is focused on delivering against its strategic priorities to achieve sustainable growth for the Group.

Uni-Bio Science's strategic priorities :

Focus on diabetes and diabetes related complications in areas such as ophthalmology and dermatology :

• 

To grow our diversified portfolio of innovative treatments and healthcare solutions through partnerships that address high unmet medical need to patients in China

• 

To realise the broad growth opportunities presented to us by the changing dynamic of the Chinese healthcare market

• 

To increase the breadth of our sales coverage beyond the key provinces where we already have a strong geographic footprint

We employ two specific elements one focused internally (solidifying foundation) and the other focused externally (maximising value). Our ultimate goal is to build a leading, sustainable organisation that delivers shareholder value by efficiently executing a number of growth strategies.

Our strategy is driven by our team of highly experienced professionals. A distinct combination of local knowledge and international experience equips us well to grow as a leading domestic healthcare company with a global outlook.

Uni-Bio Science's strength as an experienced Chinese healthcare company will enable the Group to leverage the growth drivers available to it in China, one of the world's largest healthcare markets.

• 

Strong demographics

• 

Increasing healthcare spending

• 

Healthcare reforms which will recognise and reward genuine innovation

• 

Innovative products demonstrating resistance to downward pricing pressures

• 

Government subsidies

The launch of innovative proprietary medicines, combined with the successful execution of our partnering strategy, will spur growth in our business, reduce risk and create long-term value for shareholders.